Trauma this has caused may never be healed': NZ mum and son detained by ICE
By Lauren Crimp of RNZ
A New Zealand woman and her six-year-old son who live in Washington state have been detained by US immigration, according to American media reports.
Newsweek has reported Sarah Shaw and her son, Isaac were detained on the Canadian border three weeks ago after dropping her other children off in Vancouver.
It said she was waiting for a green card and was arrested despite having some immigration documents.
The Washington Federation of State Employees (WFSE) said Shaw and her son were being held at the Dilley Immigration Processing Centre in Dilley, Texas.
WFSE said Shaw worked as a juvenile rehabilitation employee at the Echo Glen Children's Centre in Snoqualmie - run by the Washington State Department of Children, Youth and Families.
The union was calling for their immediate release.
"The trauma this has already caused for her and her son may never be healed," WFSE president Mike Yestramski, a psychiatric social worker at Western State Hospital, said.
"But our union stands ready to help and support them in any way possible. An injury to one is an injury to all."
A fundraising webpage was set up by Shaw's friend, Victoria Besancon to get Shaw and her son back to Washington.
Besancon said Shaw had a "limited ability to communicate".
"She is relying on us to get her story out."
The Ministry of Foreign Affairs and Trade said it was aware of the reports of Shaw and her son's detention, and was seeking further information.
Foreign Minister Winston Peters said there were "scant details".
"Foreign Affairs and Consular Affairs are on to it now... I can't tell you any more than that," he said.
"We're trying to find out what the details are, we haven't got those details yet."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NZ Herald
an hour ago
- NZ Herald
How Trump's funding cuts threaten US science and global innovation
Khvorova built her career by thinking boldly, but if slowdowns and cuts to federal science funding continue, she'll be forced to winnow her ambitions. 'What is happening right now is absolutely suicidal,' said Khvorova, speaking softly in Russian-accented English. 'I will stop making drugs. I will reduce my lab from 30 people to five. I will stop training scientists.' With stunning speed, the Trump Administration has over the past six months cut research dollars, terminated grants and hit the brakes on federal funding, destabilising an 80-year-old partnership between the government and universities that has made the United States a scientific superpower. The policy twists may sound arcane, but to researchers, everything is at stake. Day-to-day, Khvorova's lab is bright and buzzing. Scientists are trying to develop cures for Huntington's disease or halt the muscle loss that comes with ageing. Longer term? 'I have no clue,' Khvorova said. The Trump Administration portrays its changes as a targeted correction. Officials say grants are being terminated because they touch on topics with which the Administration disagrees, such as increasing diversity in science. Funding to specific universities has been frozen because they haven't protected Jewish students, according to the Administration. Fundamental research, Trump officials vow, will thrive. 'The money that goes to basic and blue-sky science must be used for that purpose, not to feed the red tape that so often goes along with funded research,' Michael Kratsios, director of the White House Office of Science Technology and Policy, said in a speech at the National Academy of Sciences in May. From left, Gregory Smith, Nathan Gioacchini and Philip Soglo synthesise strands of RNA at U-Mass Chan Medical School. Photo / Kate Wool, The Washington Post In contrast, a recent report from the American Association for the Advancement of Science found that President Donald Trump's budget request for 2026 – including a 40% cut to the National Institutes of Health – would slice the nation's basic research portfolio by about a third. A new report from the Congressional Budget Office found that a 10% cut to the NIH budget would result in two fewer drugs invented per year, a gradual decline that would go into full effect in 30 years. The Trump Administration's science agenda is getting pushback in courts, in Congress and at the state level, but the impacts are being felt in research institutions across the country. As of August 1, the Chan Medical School had a US$37 million ($62m)shortfall in funding because of long delays at the National Institutes of Health. Khvorova is no stranger to doing science under challenging conditions. She trained at Moscow State University in the waning days of the Soviet Union, when there was sometimes no hot water, no reagents for experiments, no salaries. Even that has not prepared her for the abrupt policy swings that threaten the unique American research system. 'We are working on developing cures, which are not politically oriented,' Khvorova said. 'Democrats age, and Republicans age.' Disruptions will ripple over decades, since no one can predict what science breakthroughs in the lab will turn into world-changing innovations. Khvorova's work built off years of federally funded research into soil-dwelling microscopic roundworms that revealed short strands of RNA perform like symphony conductors, controlling the activity of genes and turning their volume down. Worcester, a gritty former mill city in Central Massachusetts, is home to two Nobel laureates and an RNA Therapeutics Institute that has spawned 12 start-ups. Alnylam Pharmaceuticals, a company based on the phenomenon originally discovered in roundworms in labs at Chan Medical School and the Carnegie Institution of Washington, has discovered six drugs now approved for diseases that include rare genetic conditions and high cholesterol. The company's market capitalisation has soared to more than US$50 billion, and it has 2200 employees. Basic research 'is almost like the starter when you bake sourdough bread. You can't make the bread without it,' said John Maraganore, who led Alnylam for nearly two decades before he stepped down in 2021. 'Girls just wanna have (NIH) funding' In the labyrinthine, slightly cluttered labs at Chan Medical School, scientists tend to high-end instruments with geeky names like 'Dr Oligo', using them to synthesise strands of RNA aimed at treating fatal forms of dementia or diseases that cause muscles to waste away. Under sterile hoods, they grow millions of mouse liver cells for experiments. In a small room called the 'wormhole', decorated with colourful worms hanging from the door jamb like icicles, Victor Ambros, a Nobel Prize-winning worm biologist, zooms in on mutant roundworms wriggling across a yellowish agar gel. Unlike Harvard University, which has had billions of dollars in funding choked off by the Trump Administration, Chan hasn't been targeted. But it is not untouched. Like hundreds of other institutions across America, it has been thrown off stride day-to-day and week-to-week by the Trump Administration's unprecedented efforts to downsize and reshape the agencies that support science. Uncertainty looms over nearly every experiment and conversation. Slogans, not scientific sketches, are scrawled on the frosted glass wall of one office: 'We want scientific data, not alternative facts!' 'Girls just wanna have (NIH) funding' 'Science Not Silence!' More than a dozen NIH grants, out of several hundred, have been terminated, though they are tangled up in lawsuits challenging the Trump Administration's actions. About 200 employees have been laid off or furloughed, about 3% of the medical school's 6500 employees. A hiring freeze has been in place since March. Graduate school offers to nearly 90 young biomedical scientists were rescinded, though 13 spots were salvaged for next year's class. 'We have this feeling of extreme uncertainty, in a context where, previously, we could depend upon a robust system, a merit-based system that was predictable for the right reasons – the best science will get funded,' said Ambros, who shared the Nobel in medicine last year. Jesse Lehman, a graduate student who focuses on understanding the speed and dynamics of immune defences against pathogens, became hooked on science when he first felt the rush of discovering things no one else knew. There are no guarantees in this career – the contest for federal funding is exceptionally competitive. But what has fuelled the system is its reliability. The federal Government funds the best research, year after year, and scientists chase grants without worrying that the funder may lose interest in neuroscience or immunology and decide instead to buy a sports team. But now, federal funding may be there one moment and gone the next. 'I have this fear that the career that I've worked 10 years on developing just may not be viable,' Lehman said. The 20-year path to success Research institutions nationwide experience layoffs and uncertainty due to the funding reductions. Photo / Kate Wool, The Washington Post In textbooks, science is a steady march of progress. In the lab, it's an iterative process – filled with detours and dead ends that sometimes turn out to be surprises that push the field forward. In 2006, Chan biologist Craig Mello shared the Nobel Prize with Stanford University biologist Andrew Fire for the discovery of a phenomenon called RNA interference: short double strands of RNA could silence genes. It is a profound biological mechanism shared not just by tiny worms, but by humans. Other scientists built on the work, capturing the interest of venture capitalists and pharma companies. Many human diseases are caused by errant genes. What if, instead of treating patients' symptoms, doctors could give their patients drugs that just shut off the problematic ones? More than a billion dollars flowed into start-ups, but biology turned out to be a bit more complicated. Investor ebullience evaporated. Alnylam, an RNAi company, began trading below the amount of cash it had on hand, meaning investors thought its stock was less valuable than the money it had in the bank. Years of science – including a lot of chemistry – eventually turned a profound biological mechanism into a new class of safe effective drugs. 'Sickness doesn't have political boundaries,' said Phillip Zamore, a co-founder of Alnylam and a professor of biomedical sciences. 'Everyone deserves a better treatment for their disease, and I just want to make that possible. And I can't do that if my lab, my university, my colleagues' ability to do science is destroyed.' In the past few years, several biotech companies have spun out of Chan, including Comanche Biopharma, which is focused on a treatment for pre-eclampsia – a complication of pregnancy – and Atalanta Therapeutics, which is searching for cures for neurodegenerative diseases. Khvorova, a co-founder of both companies, came to the US with very little money in the mid-1990s, intending to check a box on her CV and stay a year or two. Instead, she became a 'typical example of the American Dream', as she puts it. She's an inventor named on nearly 250 patents. She just scooped up one of the most prestigious prizes in biomedical research, with a US$2.7m award. She should be on top of the world. But as she walked to her lab on a recent Tuesday, she gestured sadly at a collection of empty champagne bottles sitting high up above the cabinets in the lounge outside. Each bottle, she noted, is a trained graduate student – a reminder that most of next year's class was turned away.
RNZ News
an hour ago
- RNZ News
New Zealander detained by ICE waits for decision on six-year-old son's release
A GoFundMe has been set up for New Zealand woman Sarah Shaw and her six-year-old son Isaac. Photo: GoFundMe A friend of Sarah Shaw, a New Zealander detained at the US-Canada border , says they're expecting to hear today whether her six-year-old son will be released. Shaw and her son Isaac, who live in Washington state, were detained three weeks ago after dropping her other children off in Vancouver to catch a flight. A graduate student working towards her masters degree and working for the state in corrections, Shaw had lived in America for the past three years. Victoria Besancon explained that there were two parts to Shaw's visa, known as a "combo card" - first, an I-360 visa (the kind granting immigration status to a widow or, in Shaw's case, a victim of domestic violence), and second, an employment visa, which Shaw was granted when she was employed by the state. Shaw was waiting on both parts of her visa to be renewed, but long wait times on I-360s meant this part was not renewed at the same time as her employment visa - but Shaw did not know that, Besancon said, assuming the visa card she received in the post meant she was fully approved. Besancon said ICE (Immigration and Customs Enforcement) officials at the border could have allowed Shaw to return anyway by filing for humanitarian parole, but due to increased detainment quotas and "the atmosphere in America right now", many people were being detained who normally would not have been. Isaac, however, was being held illegally, she said, as he possessed all the right paperwork to re-enter the country. They were expecting a decision today on whether ICE would release him into her care. Despite Isaac's paperwork, he was still detained along with his mother, which meant they needed to be kept in a family detainment centre - of which there are only three, with the nearest option to Washington state in Texas. "Instead of being detained in her state of record, which is Washington, where her legal attorney would have had a much easier time defending her and requesting information, they took her multiple states away," Besancon said. If Isaac was released, it would hopefully mean Shaw could be transported to a facility in her own state. Retaining legal counsel in both states was expensive, on top of Shaw not being able to work. The GoFundMe page Besanon set up for her friend had topped US$37,000 - that is, nearly NZ$64,000 - by Tuesday evening, leaving her "speechless". "I was hoping to just get her rent covered for a month, I had no idea that this was going to get so much support." As well as donations, they had also been receiving stories from other families who had experienced similar situations. "I know it's really high on Sarah's priority list that when she does get out, to try and find a way to advocate for this." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Otago Daily Times
2 hours ago
- Otago Daily Times
Trump in element but summit unlikely to end war
"I love deadlines," Douglas Adams, author of The Hitchhiker's Guide to the Galaxy , said. "I like the whooshing sound they make as they fly by." United States President Donald Trump sets deadlines for more complicated reasons that purport to be tactical, but he too is addicted to the whooshing sound they make when he breaks them. His latest display of disdain for the deadlines he sets himself began in mid-July, when he gave Russia a 50-day deadline to agree to a ceasefire in its war against Ukraine. A week later, in an apparent fit of temper over President Vladimir Putin's relentless nightly attacks on Ukrainian cities, Trump moved the deadline up by a month, to August 8. Russia's penalty for missing that deadline was allegedly going to be American "secondary tariffs" against other countries that continue to buy Russian oil, notably China, India and Turkey. "I used trade for a lot of things, but it's great for settling wars," Trump boasted — only to discover, not for the first time, that his intended targets were able to push back. Trump declared, again before the actual deadline rolled around, that India's new tariff would be 50%, not 25%, if it did not stop buying heavily discounted Russian oil. Prime Minister Narendra Modi immediately declared that he was ready to "pay a huge price" rather than let the US dictate India's trade policies — and Trump did not even try it on with China or Turkey. So with no leverage in Moscow, his deadline for a Russian ceasefire passed unmentioned. Instead, he sent his favourite emissary, real estate developer Steve Witkoff, to make a new offer: a one-on-one meeting between Trump and Putin in which the two men would make a deal without the Ukrainians, the European Nato countries, or anybody else present. Putin jumped at the chance, as it will be his first face-to-face meeting with a US president since 2021. (He was being boycotted because of his invasion of Ukraine, but this is presumably one of Russia's rewards for agreeing to a "summit".) However, what Trump hopes to get out of it is less obvious. Although Trump is very much in thrall to Vladimir Putin, who he mistakenly believes to be his personal friend, he knows that a full Russian conquest of Ukraine would not look good on his record. His real goal is to win the Nobel Peace Prize in order to end the shame of having seen Barack Obama get one first. For that, he needs a longer-lasting "peace". This need not be a permanent peace settlement that includes an independent Ukraine. Trump really believes in "America First", and Ukraine's long-term fate is of no interest to him. But he must persuade Putin to accept only a partial victory now (and maybe final conquest later) in order to portray himself to the Norwegian Nobel committee as a plausible peacemaker. This explanation sounds so stupid and ridiculous that people have difficulty in taking it seriously, but it does explain why Trump has tried so hard to bully first one side (Ukraine), then the other side (Russia), and now back to Ukraine, into signing that kind of nothing-settled ceasefire. If you still question that analysis, consider the fact that Trump regularly indulges in extended public rants about the sheer injustice of Obama getting a Nobel Peace Prize and leaving him still without one. So when Putin dangles the prospect of a one-on-one summit before Witkoff, of course Trump is tempted, even if it would impose a disadvantageous ceasefire on Ukraine. However, there will probably not be a complete sell-out of Ukraine in Alaska, for two reasons. The first is that Putin, rightly or wrongly, is convinced that he is now winning the war by sheer weight of numbers, and that it is only a matter of time until Ukraine collapses. In that case, why would he now trim his maximal aspirations for the sake of a ceasefire? Those aspirations include Russian sovereignty over Crimea and the four south-eastern regions of Ukraine (including the yet unconquered parts), and permanent neutrality and a much-reduced army for Ukraine. In the long run, Putin aspires to "reunite" all of Ukraine with Russia under one pretext or another, but a decisive military victory might make it possible now. The other reason to assume that the Alaskan summit is unlikely to end the war is the fact that if Trump does completely sell out Ukraine, the Ukrainians will go on fighting anyway. They would be fighting at a worse disadvantage and facing a bigger likelihood of eventual conquest, but they know that wars can have unpredictable outcomes until the next-to-last moment. And whatever happens, Trump will go on setting deadlines and then missing them. Just like he did in the real estate business. • Gwynne Dyer is an independent London journalist.
